// Oncology · AI-Native · Pre-CDA Inquiries Only

From idea
to IND —
entirely in silico.

eSynThera AI is the first company to replace
the traditional drug discovery pipeline with
a fully computational workflow. No wet lab.
No physical infrastructure. AI, end to end.

Request an Introduction Learn More
◆AI-Native Drug Discovery
◆Idea to IND — In Silico
◆Oncology · Rheumatology · Cardiovascular · Renal · Metabolic · Obesity
◆Zero Wet Lab
◆GPU-Native Workflows
◆AI-Native Drug Discovery
◆Idea to IND — In Silico
◆Oncology · Rheumatology · Cardiovascular · Renal · Metabolic · Obesity
◆Zero Wet Lab
◆GPU-Native Workflows
"NVIDIA and Lilly are bringing together the best of our industries to invent a new blueprint for drug discovery — one where scientists can explore vast biological and chemical spaces in silico before a single molecule is made."

— Jensen Huang, NVIDIA CEO · J.P. Morgan Healthcare Conference

Built.
That blueprint exists. We built it.
Running.
Operational today. Not a roadmap.
The Pipeline

Every step.
Computational.
No exceptions.

01 ——
Target Identification
AI-driven identification of disease-relevant targets in high-value oncology indications.
02 ——
Candidate Design
Generative AI models design therapeutic candidates optimized across multiple parameters simultaneously.
03 ——
In Silico Screening
Large-scale computational screening replaces months of physical laboratory work.
04 ——
IND Package
AI-generated regulatory documentation and preclinical data packages — ready for filing.
We didn't build a drug company
that uses AI.

We built an AI factory
that outputs drugs.

Traditional drug discovery costs $2.6 billion and takes 12 years on average. The bottleneck is not biology — it is the physical infrastructure required to test hypotheses. eSynThera eliminates that infrastructure entirely.

eSynThera AI is the world's first AI-native drug discovery infrastructure — purpose-built to partner with biopharmaceuticals, biotechs, and key stakeholders to transform how humanity addresses disease across every indication.

▸
AI-Only Architecture No physical laboratory. No reagents. No equipment. Pure compute.
▸
Disease Agnostic Targeting the most challenging problems across oncology, rheumatology, infectious disease, cardiovascular, renal, metabolic disease, obesity, and beyond — any indication where AI can outpace conventional drug discovery.
▸
GPU-Native Workflows Built from the ground up for accelerated computing infrastructure.
▸
IP Protected Core technology under active protection. Technical details shared only under appropriate agreements.

// Partnerships · Investment · Infrastructure

The right conversation
starts with the
right introduction.

We do not share technical details without a formal agreement in place. If you represent a potential infrastructure, investment, or strategic partner, we welcome the conversation.

hello@esynthera.ai